The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years.

The FDA is adopting a new regulatory framework that will change the criteria for approval of COVID-19 vaccines.

US growth likely to slow to 1.6% this year, hobbled by Trump's trade wars, OECD says. U.S. economic growth will slow to 1.6% this year from 2.8% last year as President ...

The U.S. Food and Drug Administration has approved a new lower-dose vaccine for active immunization against COVID-19 caused ...

Unpredictable and politically driven regulatory approaches cultivate an environment of enormous uncertainty for vaccine ...

Moderna MRNA announced the FDA approval for mRNA-1283, its next-generation refrigerator-stable COVID-19 vaccine, though for a ...

Authorities investigate after 8 injured in Colorado attack by man they say yelled 'Free Palestine' ...

The FDA approved Moderna’s lower-dose COVID-19 vaccine, but only for individuals aged 65 years or older and people aged 12 to ...

The U.S. approved a new COVID-19 vaccine made by Moderna late Friday but with limits on who can use it — not a replacement ...

Vaccination rates across the country have continued to fall since the height of the pandemic, but the coronavirus never ...

The Odessa American is the leading source of local news, information, entertainment and sports for the Permian Basin.

The FDA is implementing stricter guidance for the approval of COVID-19 vaccines, according to a paper published in The New England Journal of Medicine.